FDA Accepts NDA for Avatrombopag in Pediatric Thrombocytopenia
Results from the phase 3 AVA-PED-301 trial support the FDA decision for avatrombopag in pediatric thrombocytopenia.
Related Articles
2025 FDA-AACR Workshop: DPD Deficiency and Weighing Potential Harms
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with…
Optimizing antibody-drug conjugates with computational modelling
Melissa Calopiz, University of Michigan, Ann Arbor, MI, explores the use of SimADC, a computational model for designing and evaluating antibody-drug conjugates (ADCs). By simulating…
India Emerges as Global Pharma’s Capability Cntre Hub: A Look at the Driving Forces and Challenges
India is witnessing a surge in global pharmaceutical companies establishing and expanding their presence, with Hyderabad emerging as a key…
Predicting Treatment Response in Patients With HR-positive, HER2-negative Breast Cancer
Presentations at the 2024 San Antonio Breast Cancer Symposium examined ways to predict responses to treatments for HR+ HER2- breast cancer.
Volume 2024 Issue 63 | JNCI Monographs | Oxford Academic
Publishes monographs dealing with cancer and closely related research fields, or related groups of papers on specific subjects of importance to cancer research.
Donate to Research and Education Fund web page
Is this donation tax deductible? Society Of Surgical Oncology Inc is a 501(c)3 tax-exempt organization and your donation is tax-deductible within the guidelines of U.S.…
Elacestrant With Targeted Agents May Overcome ET Resistance in Breast Cancer
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD
Dr Herrera explains why N+AVD is a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin lymphoma.
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study
AbstractBackground. Patients with a germline BRCA pathogenic variant (gBRCA-PV) and advanced high grade ovarian carcinoma (aHGOC) experience higher hematol
